Archives

Choose a date range

From To

Choose one or more categories

Categories:



 


Aptuit names Paul Overton EVP, business development & marketing

Tuesday, July 22, 2014 08:00 AM

Aptuit, a provider of integrated early to mid-phase drug development services, has appointed Paul D. Overton, Ph.D., executive vice president, business development and marketing, making him responsible for all of Aptuit's sales and marketing activities.

More... »

WIRB Copernicus Group

Ruthigen treats first human subjects in clinical trial for RUT58-60

Tuesday, July 22, 2014 08:00 AM

Ruthigen, a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, has treated the first human subjects with its drug candidate RUT58-60 in a 30 patient, 21-day skin irritation trial, which is expected to be completed in August.

More... »

CRF Health eCOA webinar series

Allergan to restructure, cutting 1,500 employees

Monday, July 21, 2014 03:35 PM

As a result of a review of its operations and processes, Allergan will execute a restructuring it estimates will deliver annual pre-tax savings of approximately $475 million in calendar year 2015. Allergan will focus resources on the highest value opportunities, streamline its organizational structure, simplify processes and interfaces, optimize site footprints and enhancie strategic sourcing of goods and services.

More... »

Alzheimer's disease market forecast to reach nearly $12B by 2023

Monday, July 21, 2014 03:29 PM

Decision Resources Group has found the market for Alzheimer's disease (AD) therapies will more than triple, reaching nearly $12 billion by 2023, largely due to the forecasted launch of the first disease-modifying therapies (DMTs), a landmark event in AD treatment.

More... »

INC Research drives deeper site connections through strengthened study startup effort

Monday, July 21, 2014 03:27 PM

As part of an effort to foster strong site relationships—to optimize timelines and deliver rapid study startup for global clinical trials—and establish the foundation for successful collaboration across the duration of a study, North Carolina-based CRO INC Research has promoted Carol Aliyar to senior vice president, study startup.

More... »

Global biosimilars market expected to reach $35 billion by 2020

Monday, July 21, 2014 03:23 PM

A new report by Allied Market Research (AMR), Global biosimilars/follow-on-biologics market (types, applications and geography)--Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013-2020, suggests the global biosimilars market could reach $35 billion by 2020 from the estimated $1.3 billion in 2013.

More... »

Accovion continues expansion of European presence

Monday, July 21, 2014 03:14 PM

Germany-based CRO Accovion has expanded its European presence. The company, already active in more than 20 countries, has established a subsidiary in Milan, Italy, naming Verónica de Lázaro country director.

More... »

E-clinical software market expected to reach $6.52 billion by 2020

Monday, July 21, 2014 03:08 PM

According to a new market report published by Transparency Market Research (TMR), E-Clinical Solution Software Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020, the e-clinical solution software market, valued at $3 billion in 2014, is expected to grow at a CAGR of 13.8% from 2014 to 2020 to reach an estimated value of $6.52 billion in 2020.

More... »

GVK Bio launches new clinical development service offering

Monday, July 21, 2014 03:06 PM

India-based GVK Biosciences has unveiled a new brand, Clinogent, in the clinical development industry. Clinogent provides end-to-end clinical development services, from bioequivalence studies for generic pharma to late phase patient-based clinical studies. It offers solutions to complex data analysis and medical communication problems.

More... »

AstraZeneca reveals designs for new U.K. global R&D center, corporate headquarters

Monday, July 21, 2014 03:03 PM

AstraZeneca revealed its proposed designs for its new global R&D center and corporate headquarters in Cambridge, U.K. The facility, which will be located on the Cambridge Biomedical Campus (CBC), includes the global center, an R&D enabling building and an energy center.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs